Veradermics (MANE) vs Mirum Pharmaceuticals (MIRM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Mirum Pharmaceuticals is the larger company by market cap ($5.24 billion vs $4.64 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MANE | MIRM |
|---|---|---|
| Share price | $110.95 | $80.64 |
| Market cap | $4.64B | $5.24B |
| 1-day change | +1.83% | +1.75% |
| YTD return | — | +2.09% |
| 1-year return | — | +9.36% |
| 5-year return | — | +371.03% |
| EPS (TTM) | $-4.32 | $-14.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $521.31M |
| Revenue growth (YoY) | — | +54.74% |
| Net income (latest FY) | $-70.00M | $-23.36M |
| Operating margin | — | -4.25% |
| Net margin | — | -4.48% |
| 52-week high | $131.24 | $130.00 |
| 52-week low | $32.00 | $63.23 |
| Distance from 52-week high | -15.46% | -37.97% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +47.36% | +80.79% |
| Average volume | 730.99K | 693.63K |
| Shares outstanding | 41.78M | 64.93M |
| Employees | 37 | 433 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Veradermics
MANE stock →Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
About Mirum Pharmaceuticals
MIRM stock →Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 433 employees
MANE vs MIRM FAQ
Which is bigger, Veradermics or Mirum Pharmaceuticals?
Mirum Pharmaceuticals (MIRM) is larger, with a market capitalization of $5.24B compared with $4.64B for Veradermics (MANE).
Are Veradermics and Mirum Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.